Electrochemical immunosensing of ST2: A checkpoint target in cancer diseases
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Torrente-Rodríguez, Rebeca M.
- dc.contributor.author Muñoz-San Martín, Cristina
- dc.contributor.author Gamella, Maria
- dc.contributor.author Pedrero, María
- dc.contributor.author Martínez Bosch, Neus
- dc.contributor.author Navarro Medrano, Pilar
- dc.contributor.author García de Frutos, Pablo
- dc.contributor.author Pingarrón, José M.
- dc.contributor.author Campuzano, Susana
- dc.date.accessioned 2021-12-22T07:45:22Z
- dc.date.available 2021-12-22T07:45:22Z
- dc.date.issued 2021
- dc.description.abstract A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed carbon electrodes (SPCEs). Magnetic immunoconjugates built on the surface of carboxylic acid-microsized magnetic particles (HOOC-MBs) were used to selectively capture ST2. A biotinylated secondary antibody further conjugated with a streptavidin peroxidase conjugate (Strep-HRP) was used to accomplish the sandwiching of the target protein. The immune platform exhibits great selectivity and a low limit of detection (39.6 pg mL-1) for ST2, allowing the determination of soluble ST2 (sST2) in plasma samples from healthy individuals and patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in only 45 min once the immunoconjugates have been prepared. The good correlation of the obtained results with those provided by an ELISA kit performed using the same immunoreagents demonstrates the potential of the developed strategy for early diagnosis and/or prognosis of the fatal PDAC disease.
- dc.description.sponsorship The financial support of PID2019-103899RB-I00 to S.C. (Spanish Ministerio de Ciencia e Innovación), RTI2018-095672-B-I00 to P.G-F (Spanish Ministerio de Ciencia, Innovación y Universidades) S2018/NMT-4349 to S.C. (Comunidad de Madrid) and PI20/00625 to P.N. (AES-ISCIII/FEDER) Research projects are gratefully acknowledged. C. Muñoz-San Martín acknowledges a predoctoral contract from Complutense University of Madrid. R.M. Torrente-Rodríguez acknowledges Talento-Contract from Comunidad de Madrid (2019-T2/IND-15965).
- dc.format.mimetype application/pdf
- dc.identifier.citation Torrente-Rodríguez RM, Martín CM, Gamella M, Pedrero M, Martínez-Bosch N, Navarro P, García de Frutos P, Pingarrón JM, Campuzano S. Electrochemical immunosensing of ST2: A checkpoint target in cancer diseases. Biosensors (Basel). 2021;11(6):202. DOI: 10.3390/bios11060202
- dc.identifier.doi http://dx.doi.org/10.3390/bios11060202
- dc.identifier.issn 2079-6374
- dc.identifier.uri http://hdl.handle.net/10230/51998
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Biosensors (Basel). 2021;11(6):202
- dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-103899RB-I00
- dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/RTI2018-095672-B-I00
- dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Electrochemical immune platform
- dc.subject.keyword Human ST2
- dc.subject.keyword Pancreatic cancer
- dc.subject.keyword Plasma
- dc.title Electrochemical immunosensing of ST2: A checkpoint target in cancer diseases
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion